Unlike other therapeutic trials, oncology trials are more sensitive in nature and require specific clinical expertise to properly manage.

Many participants are required to have already undergone front- and even second lines of therapy and, only if these have failed, are they eligible for the experimental and toxic drugs often required in oncology trials. Costs are high, enrollment can be challenging, and you are often working with medically fragile patients. However, when managed properly, effective oncology trials can save lives, generate new revenue streams, and make breakthrough discoveries in a challenging therapeutic area.

According to the American Cancer Society (ACS), more than 1.5 million new cancer diagnoses will be made in 2010. While thousands of oncology drugs are being researched at any time, very few will make it all the way to market. While many barriers or reasons for failure can’t be predicted, taking control of the basics of study design and implementation can make all the difference. Taking time up front to ensure you have the right protocol, the right team, and the right technology in place can streamline clinical research.

Read the full article in the October issue of Life Science Leader.

Back to Blog